Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Diplomat Pharmacy Plummeted Today

By Brian Orelli, PhD – Updated Nov 7, 2018 at 3:33PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The specialty pharmacy is having trouble justifying its pharmacy benefit manager purchases.

What happened

Shares of Diplomat Pharmacy (DPLO) are down 27% at 2:29 p.m. EST after the company released lackluster third-quarter earnings yesterday after the closing bell.

Revenue was up 22%, but much of that gain was from the recently acquired pharmacy benefit manager (PBM) businesses, which Diplomat rebranded as CastiaRx. Revenue for the legacy specialty pharmacy segment was up a solid-enough 8% compared to the year-ago quarter.

The problem was on the bottom line where Diplomat Pharmacy barely broke even. Operating income was up substantially year over year, but the debt Diplomat took on to pay for the PBMs ate up that income.

So what

Management cut the top of its 2018 revenue guidance from $5.9 million down to $5.7 million although the bottom of the range was held at $5.5 million. Earnings-per-share guidance went up; management now expects EPS in the range of a loss of $0.10 to a profit of $0.03, up from the previous range that bottomed out at a loss of as much as $0.15. Most of the increase in EPS guidance is due to less stock-based compensation as adjusted EBITDA guidance remained unchanged.

Hands taking medications from a pharmacy shelf.

Image source: Getty Images.

Now what

Some of today's decline likely has less to do with the third-quarter performance or even 2018 guidance, and more to do with how well a lack of new information on how Diplomat Pharmacy is doing securing PBM contracts that are scheduled to start in 2019. With just two months left, investors are likely getting antsy about whether Diplomat can get new PBM business to help cover the added interest expenses.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool recommends Diplomat Pharmacy. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Diplomat Pharmacy Stock Quote
Diplomat Pharmacy

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.